PrintThe Burrill Report
The Burrill Report (April 4, 2011): Getting Back on Track (.MP3,11.95 Mb)
Cynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. It’s hoping that its reformulation of an existing treatment for Parkinson’s disease can put it on a fast path to revenue with limited investment. We spoke to Giovinazzo about the company’s strategy, the advantages of its reformulated version of the long-standing drug apomorphine, and what lessons can be drawn from the company’s approach.
April 01, 2011
http://www.burrillreport.com/article-getting_back_on_track.html
BUSINESS STRATEGY
Getting Back on Track
Podcast: April 4, 2011[Please login to post comments]
- Separate and Unequal
Generic substitution, while a good way to save payers money in the short-term, often has deleterious impact on patient care. Read More - Valeant goes hostile with $5.7B bid for Cephalon
Canadian company pressures Cephalon for faster decision. Read More - Gilead Sciences Partners with Yale University
Multi-year deal to discover new cancer therapies. Read More - Wrecked ‘em? Damn Near Killed Him
Studies of routine prostate cancer screening suggest they don’t prevent deaths, but lead to overdetection and overtreatment. Read More - Omeros Knee Surgery Drug Fails in Late-Stage Trial
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Pharma Companies Disclose Millions Paid to U.S. Doctors
Voluntary reporting accelerates ahead of new requirements Read More - Biota Lands Major BARDA Contract
U.S. government sees promise in Aussie flu drug. Read More - Think It, Do It
California team is developing brain-machine interfaces. Read More - Obama Outlines U.S. Energy Security Plan
President pledges support for development of advanced biofuels. Read More - Biosimilars Present Opportunities and Challenges to Russia
If country hopes to export these medicines, a 21st century, state of the art, internationally recognized and harmonized regulatory system will be a fundamental requirement. Read More
.gif)
- Valeant Pharma Offers to Acquire Cephalon for $5.7 Billion
Bloomberg - Bayer plans to raise BRIC revenue to 10 bln-paper
Reuters - States Weigh Fighting Meth With Drug Prescriptions
The New York Times - Protalix Plans Human Clinical Tests of Medication for Rare Fabry's Disease
Bloomberg - Branded drug prices soar as generic pressure rises
Reuters - China to ban smoking at indoor public places
Reuters - A Panel Decides Washington State’s Health Care Costs
The New York Times - Supreme Court Rules Against Zicam Maker
The New York Times - Anxiety Over Radiation Drives a Sales Surge for a Drug Against Thyroid Cancer
The New York Times - HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success
Bloomberg